The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.
The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.
Study Type
OBSERVATIONAL
Enrollment
1,000
Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.
Union Hospital, Tongji Medical college, Huazhong University of Science and Technology
Wuhan, Hubei, China
progression-free survival
The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.
Time frame: A two-year period after starting treatment (Regular follow-up every three months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)
Overall survival
The survival time aftering receiving immunotherapy combined with or without chemotherapy as first-line treatment.
Time frame: A three-year period after starting treatment (Regular follow-up every six months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.